通过增加突触可塑性,增强ERK活性延长了胺的抗抑郁作用
Z Zack Ma1,2, Natalie J Guzikowski1,2, Ji-Woon Kim1,2
1Department of Pharmacology, Vanderbilt University, Nashville, TN, USA.
概括
维护胺
科学领域:
- 神经科学
- 药理学
- 分子精神病学
背景情况:
- 重复的胺治疗提供了快速的抗抑郁作用,但会引起副作用,因此需要从单剂量开始采取持续作用的策略.
- 胺的抗抑郁作用与关键的神经通路CA3-CA1突触的突触强化有关.
研究的目的:
- 通过准细胞内信号通路来延长胺的抗抑郁作用的方法.
- 探索双特异性酸酶6 (DUSP6) 和细胞外信号调节激酶 (ERK) 在介导胺的持续作用中的作用.
主要方法:
- 药理上抑制DUSP6,以增强胺基因的活性.
- 评估CA3-CA1突触中的突触强化.
- 在动物模型中评估类似抗抑郁药的行为效应.
- 在激发性神经元中选择性删除热胺受体激酶B (TrkB),以确定其作用.
主要成果:
- 在CA3-CA1突触中抑制DUSP6增强了胺诱导的突触强化.
- DUSP6抑制延长了胺类抗抑郁药的行为效应长达2个月.
- DUSP6抑制对突触和行为结果的影响取决于刺激神经元中的TrkB信号.
结论:
- 通过DUSP6抑制暂时增加细胞外信号调节激酶 (ERK) 活性可以维持胺的抗抑郁作用.
- 针对下游的细胞内信号传输,特别是依赖TrkB的途径,为延长胺的治疗效果提供了一个有希望的策略.
- 这种方法解决了单剂量胺剂持续抗抑郁作用的临床需求.
更多相关视频
05:42Elevated Plus Maze Test Combined with Video Tracking Software to Investigate the Anxiolytic Effect of Exogenous Ketogenic Supplements
Published on: January 7, 2019
30.7K
09:51Recording Synaptic Plasticity in Acute Hippocampal Slices Maintained in a Small-volume Recycling-, Perfusion-, and Submersion-type Chamber System
Published on: January 1, 2018
11.5K
相关概念视频
Electroconvulsive Therapy
18
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
18
Antidepressant Drugs: MAOIs and Other Agents
164
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
164
Drugs Affecting Neurotransmitter Release or Uptake
876
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
876
Antiepileptic Drugs: Potassium Channel Activators
127
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
127
Sedatives and Hypnotics Drugs: Miscellaneous Agents
129
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
129
Long-term Depression
30.4K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
30.4K
